Quarterly ResultMay 15, 2026, 04:27 PM
Plus Therapeutics Q1 Net Loss $(6.9)M; Cash $15.1M; REYOBIQ ODD
AI Summary
Plus Therapeutics reported a net loss of $(6.9) million, or $(1.05) per basic share, for Q1 2026, compared to a net loss of $(17.4) million, or $(29.86) per basic share, in Q1 2025. The company's cash and investments balance increased to $15.1 million as of March 31, 2026, following a $15 million public offering. Key business updates include FDA Orphan Drug Designation for REYOBIQ, expanded payer coverage for CNSide to 81 million lives, and progress on clinical trials and commercial readiness.
Key Highlights
- Q1 2026 net loss was $(6.9) million, a significant improvement from $(17.4) million in Q1 2025.
- Net loss per basic share was $(1.05) in Q1 2026, compared to $(29.86) in Q1 2025.
- Cash and investments balance increased to $15.1 million as of March 31, 2026, from $8.6 million at year-end 2025.
- Completed an upsized public offering generating $15 million in gross proceeds.
- REYOBIQ received U.S. FDA Orphan Drug Designation for pediatric malignant gliomas.
- CNSide expanded payer coverage to approximately 81 million covered lives, adding a fourth national payer.
- Q1 2026 revenue was $1.0 million, slightly down from $1.1 million in Q1 2025.
- Operating loss for Q1 2026 was $(7.1) million, compared to $(3.5) million in Q1 2025.
Price Impact
More from PSTV